Acoramidis

Acoramidis (AG10) is an investigational transthyretin stabilizer developed to treat transthyretin amyloid cardiomyopathy. It is delivered by mouth. An alternative treatment is tafamidis.[1][2][3]

Acoramidis
Clinical data
ATC code
  • None
Identifiers
  • 3-[3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC15H17FN2O3
Molar mass292.310 g·mol−1
3D model (JSmol)
  • CC1=C(C(=NN1)C)CCCOC2=C(C=CC(=C2)C(=O)O)F
  • InChI=1S/C15H17FN2O3/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20)
  • Key:WBFUHHBPNXWNCC-UHFFFAOYSA-N

References
  1. "Trial demonstrates potential of acoramidis for transthyretin amyloid cardiomyopathy". www.escardio.org.
  2. Masri, Ahmad; Aras, Mandar; Falk, Rodney H.; Grogan, Martha; Jacoby, Daniel; Judge, Daniel P.; Shah, Sanjiv Jayendra; Witteles, Ronald; Ji, Alan X.; Wong, Paul W.; Cao, Xiaofan; Vanlandingham, Rebecca; Katz, Leonid; Sinha, Uma; Fox, Jonathan C.; Maurer, Mathew S. (March 2022). "Long-Term Safety and Tolerability of Acoramidis (Ag10) in Symptomatic Transthyretin Amyloid Cardiomyopathy: Updated Analysis from an Ongoing Phase 2 Open-Label Extension Study". Journal of the American College of Cardiology. 79 (9): 227. doi:10.1016/S0735-1097(22)01218-9. S2CID 247906494.
  3. Campbell, Courtney M.; Zhang, Kathleen; Lenihan, Daniel J.; Witteles, Ronald (April 2022). "Developing Therapy for Transthyretin Amyloidosis". The American Journal of Medicine. 135: S44–S48. doi:10.1016/j.amjmed.2022.01.002. PMID 35077703. S2CID 246225610.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.